142 related articles for article (PubMed ID: 2159563)
1. Evidence suggesting that virulence maps to the P1 region of the coxsackievirus B4 genome.
Ramsingh A; Hixson A; Duceman B; Slack J
J Virol; 1990 Jun; 64(6):3078-81. PubMed ID: 2159563
[TBL] [Abstract][Full Text] [Related]
2. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype.
Caggana M; Chan P; Ramsingh A
J Virol; 1993 Aug; 67(8):4797-803. PubMed ID: 8392614
[TBL] [Abstract][Full Text] [Related]
3. A point mutation in the VP4 coding sequence of coxsackievirus B4 influences virulence.
Ramsingh AI; Collins DN
J Virol; 1995 Nov; 69(11):7278-81. PubMed ID: 7474153
[TBL] [Abstract][Full Text] [Related]
4. Genetics of coxsackievirus B3 cardiovirulence.
Tracy S; Tu Z; Chapman N; Hufnagel G
Eur Heart J; 1995 Dec; 16 Suppl O():15-7. PubMed ID: 8682085
[TBL] [Abstract][Full Text] [Related]
5. Mutation variants generated from nonvirulent coxsackievirus B3 acquire virulence phenotypes by active virus replication.
Seo I; Jee Y; Ahn J; Jun EJ; Kim D; Joo CH; Kim YK; Lee H
Intervirology; 2007; 50(6):447-53. PubMed ID: 18268408
[TBL] [Abstract][Full Text] [Related]
6. Genomic regions of neurovirulence and attenuation in Theiler murine encephalomyelitis virus.
Calenoff MA; Faaberg KS; Lipton HL
Proc Natl Acad Sci U S A; 1990 Feb; 87(3):978-82. PubMed ID: 2153981
[TBL] [Abstract][Full Text] [Related]
7. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.
Knowlton KU; Jeon ES; Berkley N; Wessely R; Huber S
J Virol; 1996 Nov; 70(11):7811-8. PubMed ID: 8892902
[TBL] [Abstract][Full Text] [Related]
8. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates.
Beck MA; Shi Q; Morris VC; Levander OA
Nat Med; 1995 May; 1(5):433-6. PubMed ID: 7585090
[TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice.
Tracy S; Chapman NM; Tu Z
Arch Virol; 1992; 122(3-4):399-409. PubMed ID: 1310000
[TBL] [Abstract][Full Text] [Related]
10. The viral genome in experimental murine Coxsackievirus B3 myocarditis: a Northern blotting analysis.
Okada I; Matsumori A; Kawai C; Yodoi J; Tracy S
J Mol Cell Cardiol; 1990 Sep; 22(9):999-1008. PubMed ID: 2177795
[TBL] [Abstract][Full Text] [Related]
11. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route.
Bopegamage S; Borsanyiová M; Vargová A; Petrovicová A; Benkovicová M; Gomolcák P
Acta Virol; 2003; 47(4):245-51. PubMed ID: 15068380
[TBL] [Abstract][Full Text] [Related]
12. Characterization of an infectious cDNA copy of the genome of a naturally occurring, avirulent coxsackievirus B3 clinical isolate.
Lee CK; Kono K; Haas E; Kim KS; Drescher KM; Chapman NM; Tracy S
J Gen Virol; 2005 Jan; 86(Pt 1):197-210. PubMed ID: 15604447
[TBL] [Abstract][Full Text] [Related]
13. A point mutation in VP1 of coxsackievirus B4 alters antigenicity.
Halim S; Ramsingh AI
Virology; 2000 Mar; 269(1):86-94. PubMed ID: 10725201
[TBL] [Abstract][Full Text] [Related]
14. Genetics of coxsackievirus virulence.
Chapman NM; Ramsingh AI; Tracy S
Curr Top Microbiol Immunol; 1997; 223():227-58. PubMed ID: 9294932
[No Abstract] [Full Text] [Related]
15. Strains of coxsackie virus B4 differed in their ability to induce acute pancreatitis and the responses were negatively correlated to glucose tolerance.
Hindersson M; Orn A; Harris RA; Frisk G
Arch Virol; 2004 Oct; 149(10):1985-2000. PubMed ID: 15669109
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the 5' NTR and the Non-Structural Protein 3A of the Coxsackievirus B3 Selectively Attenuate Myocarditogenicity.
Massilamany C; Gangaplara A; Basavalingappa RH; Rajasekaran RA; Vu H; Riethoven JJ; Steffen D; Pattnaik AK; Reddy J
PLoS One; 2015; 10(6):e0131052. PubMed ID: 26098885
[TBL] [Abstract][Full Text] [Related]
17. Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.
Elmastour F; Jaïdane H; Benkahla M; Aguech-Oueslati L; Sane F; Halouani A; Engelmann I; Bertin A; Mokni M; Gharbi J; Aouni M; Alidjinou EK; Hober D
Virulence; 2017 Aug; 8(6):908-923. PubMed ID: 27792461
[TBL] [Abstract][Full Text] [Related]
18. Outcome of challenge with Coxsackievirus B4 in young mice after maternal infection with the same virus during gestation.
Bopegamage S; Precechtelova J; Marosova L; Stipalova D; Sojka M; Borsanyiova M; Gomolcak P; Berakova K; Galama JM
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):184-90. PubMed ID: 22066931
[TBL] [Abstract][Full Text] [Related]
19. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice.
Tracy S; Höfling K; Pirruccello S; Lane PH; Reyna SM; Gauntt CJ
J Med Virol; 2000 Sep; 62(1):70-81. PubMed ID: 10935991
[TBL] [Abstract][Full Text] [Related]
20. Group B coxsackievirus virulence.
Tracy S; Gauntt C
Curr Top Microbiol Immunol; 2008; 323():49-63. PubMed ID: 18357765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
